Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Diamedica Therapeutics Inc (DMAC)

Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Author
Three (3) Stocks Under $10 That Insiders Are Buying  MarketBeat - Wed Jul 5, 2023

These small-cap names provide an opportunity that insiders are buying including deep value, growth, new technology, and AI.

DMAC : 3.93 (-0.25%)
ADT : 7.29 (-0.95%)
CMTL : 3.16 (+2.27%)
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023 Business Wire - Mon May 8, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today...

DMAC : 3.93 (-0.25%)
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer Business Wire - Tue Apr 11, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David...

DMAC : 3.93 (-0.25%)
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results Business Wire - Tue Mar 28, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 3.93 (-0.25%)
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023 Business Wire - Mon Mar 20, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today...

DMAC : 3.93 (-0.25%)
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference Business Wire - Mon Mar 13, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 3.93 (-0.25%)
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors Business Wire - Mon Mar 6, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...

DMAC : 3.93 (-0.25%)
KPTI : 0.7602 (-1.38%)
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results Business Wire - Wed Nov 9, 2022

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 3.93 (-0.25%)
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022 Business Wire - Mon Nov 7, 2022

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 3.93 (-0.25%)
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference Business Wire - Mon Oct 31, 2022

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 3.93 (-0.25%)

Barchart Exclusives

3 AI Stocks to Buy Instead of Super Micro Computer Barchart - Sat Aug 31, 7:30AM CDT
Following a significant drop in Super Micro Computer's stock due to a delayed 10-K filing and accounting concerns, investors are exploring alternative AI infrastructure stocks like Dell, Arista Networks, and Pure Storage, which offer strong growth prospects in the rapidly expanding AI market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot